These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Role of Mucosal Immunity in Pertussis. Solans L; Locht C Front Immunol; 2018; 9():3068. PubMed ID: 30692990 [TBL] [Abstract][Full Text] [Related]
25. Live pertussis vaccines: will they protect against carriage and spread of pertussis? Locht C Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S96-S102. PubMed ID: 28341014 [TBL] [Abstract][Full Text] [Related]
26. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP Clin Vaccine Immunol; 2009 Sep; 16(9):1344-51. PubMed ID: 19625486 [TBL] [Abstract][Full Text] [Related]
27. Bordetella pertussis from functional genomics to intranasal vaccination. Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035 [TBL] [Abstract][Full Text] [Related]
28. Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative. Solans L; Debrie AS; Coutte L; Locht C Vaccine; 2021 May; 39(21):2843-2849. PubMed ID: 33896662 [TBL] [Abstract][Full Text] [Related]
29. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926 [TBL] [Abstract][Full Text] [Related]
30. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220 [TBL] [Abstract][Full Text] [Related]
31. Pertussis: Where did we go wrong and what can we do about it? Locht C J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992 [TBL] [Abstract][Full Text] [Related]
32. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. Li R; Lim A; Phoon MC; Narasaraju T; Ng JK; Poh WP; Sim MK; Chow VT; Locht C; Alonso S J Virol; 2010 Jul; 84(14):7105-13. PubMed ID: 20444902 [TBL] [Abstract][Full Text] [Related]
33. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. Feunou PF; Bertout J; Locht C PLoS One; 2010 Apr; 5(4):e10178. PubMed ID: 20419113 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults. Buddy Creech C; Jimenez-Truque N; Kown N; Sokolow K; Brady EJ; Yoder S; Solovay K; Rubin K; Noviello S; Hensel E; Selamawi S; Bakare A; Makowski M; Lu K Vaccine; 2022 Nov; 40(47):6740-6746. PubMed ID: 36220716 [TBL] [Abstract][Full Text] [Related]
35. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM J Immunol; 2011 May; 186(9):5388-96. PubMed ID: 21430219 [TBL] [Abstract][Full Text] [Related]
36. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate. Cornford-Nairns R; Daggard G; Mukkur T J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165 [TBL] [Abstract][Full Text] [Related]
37. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection. Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570 [TBL] [Abstract][Full Text] [Related]